Northland Securities restated their buy rating on shares of Motif Bio PLC (LON:MTFB) in a report published on Thursday.

Other equities analysts have also recently issued research reports about the company. FinnCap reiterated a buy rating and set a GBX 125 ($1.62) price target on shares of Motif Bio PLC in a report on Tuesday, April 18th. Beaufort Securities reiterated a speculative buy rating and set a GBX 110 ($1.42) price target on shares of Motif Bio PLC in a report on Monday, June 5th.

Motif Bio PLC (LON:MTFB) traded down 0.83% during mid-day trading on Thursday, hitting GBX 29.75. The stock had a trading volume of 48,941 shares. The stock’s 50-day moving average is GBX 31.71 and its 200 day moving average is GBX 28.24. Motif Bio PLC has a 52 week low of GBX 21.44 and a 52 week high of GBX 68.25. The company’s market capitalization is GBX 58.28 million.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.dailypolitical.com/2017/07/07/motif-bio-plc-lonmtfb-given-buy-rating-at-northland-securities.html.

About Motif Bio PLC

Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).

Receive News & Ratings for Motif Bio PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio PLC and related companies with MarketBeat.com's FREE daily email newsletter.